If you've compared prices for semaglutide or tirzepatide, you've probably noticed a gap that seems too big to make sense: a brand-name pen can run over $1,700/month, while a compounded version of the same active ingredient is often a fraction of that. Here's what that difference actually is — and isn't.
Compounded semaglutide and tirzepatide contain the same active pharmaceutical ingredient as Ozempic®, Wegovy®, Mounjaro®, and Zepbound® — the molecules that make these medications work. The difference is who prepares the final product. Brand-name versions are manufactured at scale and carry FDA approval as a finished product. Compounded versions are prepared individually by a licensed compounding pharmacy, based on a prescription from your provider.
Brand-name pricing reflects years of clinical trials, patent protection, and marketing costs baked into a single manufacturer's product. Compounding pharmacies aren't recreating that R&D pipeline — they're preparing the same active ingredient using their own formulation and equipment, a fundamentally different cost structure.
Compounded medications are not FDA-approved as a finished product the way Ozempic® or Zepbound® are — that's a real, meaningful difference, not just paperwork. This is exactly why a licensed provider reviewing your history and a licensed compounding pharmacy both matter.
This isn't a decision to make from a price comparison alone. Your provider can walk through what's appropriate for your situation, including whether a compounded option makes sense for you specifically.
